The main objective of this study was to examine the association of tumor 18F-fluorodeoxyglucose metabolism with DRFS in patients with ER-positive, HER2-negative breast cancer treated with anthracycline-based neoadjuvant chemotherapy (NCT) followed by adjuvant endocrine therapy. Here, ERBB2 is linked to neoplasm.